AI assistant
VERTEX PHARMACEUTICALS INC / MA — Director's Dealing 2012
Mar 29, 2012
29864_dirs_2012-03-29_28c6319f-97bb-4d43-9d5e-9b1c83503bca.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK: 0000875320
Period of Report: 2012-03-28
Reporting Person: BOGER JOSHUA S (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2012-03-28 | Common Stock | M | 4000 | $15.87 | Acquired | 634949 | Direct |
| 2012-03-28 | Common Stock | S | 3500 | $40.52 | Disposed | 631449 | Direct |
| 2012-03-28 | Common Stock | S | 500 | $41.25 | Disposed | 630949 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2012-03-28 | Stock Option | $24.66 | M | 4000 | Disposed | 2012-07-21 | Common Stock (4000) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 13286 | Indirect |
| Common Stock | 300000 | Indirect |
Footnotes
F1: Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1.
F2: Open market sales reported on this line occurred at a weighted average price of $40.52 (range $40.31 to $40.91).
F3: Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F4: Open market sales reported on this line occurred at a weighted average price of $41.25 (range $41.05 to $41.42).
F5: Common stock held in grantor retained annuity trusts.
F6: Fully vested.